Maximus (NYSE:MMS) Rating Lowered to “Hold” at Wall Street Zen

Posted by on Aug 10th, 2026

Maximus (NYSE:MMS – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

Several other equities research analysts have also recently issued reports on MMS. Zacks Research cut shares of Maximus from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 27th. Weiss Ratings lowered Maximus from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, May 20th. Two investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Maximus has an average rating of “Hold”.

View Our Latest Stock Report on Maximus

Maximus Stock Up 0.0%

Shares of Maximus stock opened at $59.21 on Friday. Maximus has a 52-week low of $52.73 and a 52-week high of $100.00. The company has a 50 day moving average of $58.63 and a 200 day moving average of $67.24. The company has a quick ratio of 2.42, a current ratio of 2.42 and a debt-to-equity ratio of 0.90. The company has a market capitalization of $3.10 billion, a P/E ratio of 8.75 and a beta of 0.59.

Maximus (NYSE:MMS – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The health services provider reported $2.22 EPS for the quarter, topping the consensus estimate of $2.21 by $0.01. Maximus had a net margin of 7.07% and a return on equity of 24.91%. The company had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.33 billion. During the same quarter in the previous year, the business posted $2.16 EPS. The firm’s revenue was down 5.1% on a year-over-year basis. Maximus has set its FY 2026 guidance at 7.900-8.200 EPS. As a group, research analysts forecast that Maximus will post 8.05 EPS for the current fiscal year.

Hedge Funds Weigh In On Maximus

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in shares of Maximus in the 2nd quarter valued at $400,186,000. Reinhart Partners LLC. raised its stake in Maximus by 131.8% during the 2nd quarter. Reinhart Partners LLC. now owns 1,982,415 shares of the health services provider’s stock worth $106,575,000 after acquiring an additional 1,127,346 shares in the last quarter. Norges Bank purchased a new stake in Maximus in the fourth quarter valued at $60,393,000. River Road Asset Management LLC lifted its position in Maximus by 236.1% in the fourth quarter. River Road Asset Management LLC now owns 823,262 shares of the health services provider’s stock valued at $71,064,000 after acquiring an additional 578,326 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Maximus in the second quarter valued at $26,239,000. 97.21% of the stock is currently owned by hedge funds and other institutional investors.

Maximus News Roundup

Here are the key news stories impacting Maximus this week:

  • Positive Sentiment: Fiscal Q3 adjusted earnings were $2.22 per share, ahead of analyst estimates of approximately $2.20–$2.21 and up from $2.16 a year earlier. Higher margins also supported the quarter’s bottom-line performance. Maximus Q3 Earnings Beat Estimates, Increase Year Over Year
  • Positive Sentiment: The earnings beat, year-over-year EPS growth and stronger margins indicate that Maximus is maintaining profitability even as sales soften. Maximus Q3 Earnings Beat Estimates
  • Neutral Sentiment: Management’s fiscal Q3 earnings call focused on the quarterly performance and updated outlook, providing investors with additional context on operating trends and the company’s expectations for the remainder of fiscal 2026. Maximus Q3 2026 Earnings Call Transcript
  • Negative Sentiment: Revenue was $1.28 billion, below the $1.33 billion consensus estimate and down 5.1% year over year. The shortfall suggests softer demand or project timing is limiting growth. Maximus Fiscal Q3 Earnings Snapshot
  • Negative Sentiment: Maximus reduced fiscal 2026 EPS guidance to $7.90–$8.20, below the consensus estimate of $8.43. Revenue guidance of $5.2–$5.4 billion remains broadly in line with expectations at the midpoint, but the lower profit outlook is a key overhang for MMS. Updated Maximus Fiscal 2026 Guidance

Maximus Company Profile

(Get Free Report)

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.

See Also

Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.